{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T03:07:49Z","timestamp":1767841669567,"version":"3.49.0"},"reference-count":15,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,2]],"date-time":"2015-12-02T00:00:00Z","timestamp":1449014400000},"content-version":"vor","delay-in-days":2161,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2010,1]]},"DOI":"10.1097\/jto.0b013e3181c20063","type":"journal-article","created":{"date-parts":[[2010,2,25]],"date-time":"2010-02-25T01:39:52Z","timestamp":1267061992000},"page":"99-104","source":"Crossref","is-referenced-by-count":54,"title":["A Phase II Trial of Erlotinib Monotherapy in Pretreated Patients with Advanced Non-small Cell Lung Cancer Who Do Not Possess Active EGFR Mutations: Okayama Lung Cancer Study Group Trial 0705"],"prefix":"10.1016","volume":"5","author":[{"given":"Hiroshige","family":"Yoshioka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuyuki","family":"Hotta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuyuki","family":"Kiura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nagio","family":"Takigawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidetoshi","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shingo","family":"Harita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoichi","family":"Kuyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiko","family":"Segawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruhito","family":"Kamei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeki","family":"Umemura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Bessho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Tabata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsune","family":"Tanimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1097\/JTO.0b013e3181c20063_bib1","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1016\/S0140-6736(08)61758-4","article-title":"Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial","volume":"372","author":"Kim","year":"2008","journal-title":"Lancet"},{"key":"10.1097\/JTO.0b013e3181c20063_bib2","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa050753","article-title":"Erlotinib in previously treated non-small-cell lung cancer","volume":"353","author":"Shepherd","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1097\/JTO.0b013e3181c20063_bib3","doi-asserted-by":"crossref","first-page":"e313","DOI":"10.1371\/journal.pmed.0020313","article-title":"Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants","volume":"2","author":"Greulich","year":"2005","journal-title":"PLoS Med"},{"key":"10.1097\/JTO.0b013e3181c20063_bib4","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1200\/JCO.2005.05.4692","article-title":"Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations","volume":"24","author":"Inoue","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181c20063_bib5","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1097\/JTO.0b013e318074bc0d","article-title":"Clinical significance of epidermal growth factor receptor gene mutations on treatment outcome after first-line cytotoxic chemotherapy in Japanese patients with non-small cell lung cancer","volume":"2","author":"Hotta","year":"2007","journal-title":"J Thorac Oncol"},{"issue":"Suppl 8","key":"10.1097\/JTO.0b013e3181c20063_bib6","first-page":"viii1","article-title":"Phase III, randomised, open-label, first-line study of gefitinib (G) vs carboplatin\/paclitaxel (C\/P) in clinically selected patients (PTS) with advanced non-small-cell lung cancer (NSCLC) (IPASS)","volume":"19","author":"Mok","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1097\/JTO.0b013e3181c20063_bib7","doi-asserted-by":"crossref","first-page":"4268","DOI":"10.1200\/JCO.2007.14.8924","article-title":"Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR. 21","volume":"26","author":"Zhu","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181c20063_bib8","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1200\/JCO.2004.08.163","article-title":"Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy","volume":"22","author":"Hanna","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181c20063_bib9","doi-asserted-by":"crossref","first-page":"7276","DOI":"10.1158\/0008-5472.CAN-05-0331","article-title":"Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp","volume":"65","author":"Nagai","year":"2005","journal-title":"Cancer Res"},{"key":"10.1097\/JTO.0b013e3181c20063_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Control Clin Trials"},{"key":"10.1097\/JTO.0b013e3181c20063_bib11","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.1200\/JCO.2006.06.3958","article-title":"Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer","volume":"24","author":"Hirsch","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181c20063_bib12","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/00130404-200509000-00010","article-title":"Interstitial lung disease in patients with non-small-cell lung cancer receiving gefitinib: an analysis of risk factors and treatment outcomes in Okayama Lung Cancer Study Group","volume":"11","author":"Hotta","year":"2005","journal-title":"Cancer J"},{"key":"10.1097\/JTO.0b013e3181c20063_bib13","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/S0140-6736(05)67625-8","article-title":"Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)","volume":"366","author":"Thatcher","year":"2005","journal-title":"Lancet"},{"key":"10.1097\/JTO.0b013e3181c20063_bib14","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1038\/sj.bjc.6603466","article-title":"Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp","volume":"95","author":"Sutani","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1097\/JTO.0b013e3181c20063_bib15","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1093\/annonc\/mdn679","article-title":"Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer","volume":"20","author":"Gow","year":"2009","journal-title":"Ann Oncol"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086415329749?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086415329749?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,12]],"date-time":"2018-12-12T19:55:06Z","timestamp":1544644506000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086415329749"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,1]]}},"alternative-id":["S1556086415329749"],"URL":"https:\/\/doi.org\/10.1097\/jto.0b013e3181c20063","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2010,1]]}}}